COLL in the 13F filings
Collegium Pharmaceutical Inc · CUSIP 19459J104
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 32
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 4 listed it in both
- Shares listed
- 9,023,254
- combined, among listed positions
- Reported value
- $418m
- combined, at the quarter end
Among the 92 comparable managers: 18 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,611,642.
Managers listing COLL in Q4 2025
32 of 32 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 1,448,578 shares now+538,337
- MFS Investment Managementexisting position · 1,312,655 shares now+518,721
- Arrowstreet Capital LPexisting position · 543,773 shares now+510,060
- D. E. Shaw & Co.existing position · 653,874 shares now+264,099
- Marshall Wace LLPexisting position · 492,360 shares now+213,347
Reductions
- Walleye Capital LLCexisting position · 39,708 shares now-189,479
- Citadel Advisors LLCexisting position · 131,126 shares now-122,374
- Invesco Ltdexisting position · 1,175,041 shares now-107,930
- Millennium Management LLCexisting position · 70,283 shares now-51,903
- Jane Street Group LLCexisting position · 190,763 shares now-49,967
New positions and exits
New (5)
Exited (1)
- Winton Group Ltdwas $2.3m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2016 | 1 | $282k | n.a. | n.a. |
| Q3 2016 | 1 | $458k | n.a. | n.a. |
| Q4 2016 | 1 | $1.9m | n.a. | n.a. |
| Q1 2017 | 1 | $1.0m | n.a. | n.a. |
| Q2 2017 | 2 | $1.5m | n.a. | n.a. |
| Q3 2017 | 1 | $525k | n.a. | n.a. |
| Q4 2017 | 2 | $64m | n.a. | n.a. |
| Q1 2018 | 2 | $99m | n.a. | n.a. |
| Q2 2018 | 3 | $102m | n.a. | n.a. |
| Q3 2018 | 2 | $9.3m | n.a. | n.a. |
| Q4 2018 | 2 | $74m | n.a. | n.a. |
| Q1 2019 | 1 | $6.0m | n.a. | n.a. |
| Q2 2019 | 1 | $721k | n.a. | n.a. |
| Q3 2019 | 1 | $502k | n.a. | n.a. |
| Q4 2019 | 3 | $99m | n.a. | n.a. |
| Q1 2020 | 2 | $90m | n.a. | n.a. |
| Q2 2020 | 2 | $93m | n.a. | n.a. |
| Q3 2020 | 2 | $110m | n.a. | n.a. |
| Q4 2020 | 2 | $103m | n.a. | n.a. |
| Q1 2021 | 2 | $98m | n.a. | n.a. |
| Q2 2021 | 3 | $99m | n.a. | n.a. |
| Q3 2021 | 1 | $81m | n.a. | n.a. |
| Q4 2021 | 2 | $71m | n.a. | n.a. |
| Q1 2022 | 1 | $1.1m | n.a. | n.a. |
| Q2 2022 | 2 | $40m | n.a. | n.a. |
| Q3 2022 | 3 | $32m | n.a. | n.a. |
| Q4 2022 | 3 | $35m | n.a. | n.a. |
| Q1 2023 | 2 | $31m | n.a. | n.a. |
| Q2 2023 | 1 | $224k | n.a. | n.a. |
| Q3 2023 | 1 | $26m | n.a. | n.a. |
| Q4 2023 | 1 | $43m | 1 | 0 |
| Q1 2024 | 4 | $59m | 4 | 0 |
| Q2 2024 | 3 | $52m | 3 | 0 |
| Q3 2024 | 2 | $67m | 2 | 1 |
| Q4 2024 | 2 | $48m | 1 | 1 |
| Q1 2025 | 2 | $54m | 1 | 1 |
| Q2 2025 | 1 | $45m | 0 | 1 |
| Q3 2025 | 5 | $60m | 4 | 0 |
| Q4 2025 | 6 | $209m | 18 | 14 |
| Q1 2026 | 5 | $157m | 16 | 15 |
| Q2 2026 | 4 | $180m | 11 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
COLL and LLY →COLL and JNJ →COLL and VRTX →Choose a stock to compare with COLL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own COLL, latest filings →Back to the 13F Explorer →